Appointment of Charles Simmons as Managing Director continues to strengthen Outcome’s capabilities

Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that Charles Simmons, J.D. has been appointed to the role of Managing Director in its Boston office. The firm continues to expand its Life Sciences and Healthcare practices deploying its unique market-aligned, strategy-driven platform, providing mergers and acquisitions, partnerships, and strategic advisory services.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240807978894/en/

Charles Simmons, Managing Director, Outcome Capital (Photo: Business Wire)

“At this time of dynamic change in healthcare due to technology-driven advances in life sciences, I am excited to join a team of exceptional professionals with deep strategic knowledge on Outcome Capital’s premium and growing platform,” commented Charles.

Charles Simmons brings over 25 years’ experience as a business leader driving transformational change in companies across the Life Sciences sector. His background includes extensive global work in a range of corporate settings (public, development stage, private equity/PE) and sectors (pharma, pharma services, med-tech). He has a proven track record partnering with investors, boards, CEOs, and other key stakeholders addressing significant business issues, articulating and building agreement around transformational change, and providing hands-on leadership to deliver results including leading multi-billion-dollar transactions.

Dr. Oded Ben-Joseph, Managing Partner at Outcome Capital commented, “We continue to expand our specialized strategy-led execution model, which allow us to provide premium services to our clients, successfully navigating their businesses through significant inflection points, and toward successful transactions. Charles’ sector expertise and M&A experience will be instrumental in Outcome’s growth and is exemplary of the firm’s underlying philosophy of combining scientific and clinical expertise with financial and transactional acumen.”

Prior to joining Outcome, Charles was Chief Growth Officer at Corium, Inc., a commercial-stage biopharmaceutical company. He was an instrumental leader in the divestiture of G&W Laboratories’ historic businesses and subsequent investment into Flipt LLC, a mission-driven healthcare technology and services company. Previously as President, Commercial Development & Operations with Idis Pharmaceuticals, a pharma services business, Charles drove improvements in operational metrics and led the group that re-entered the clinical sourcing business. Prior to that, Charles served as VP, Corporate Development at Bristol-Myers Squibb Company (BMS) for almost a decade where he was instrumental in several transactions that transformed BMS. Charles launched his career as an Associate for the major New York law firm, Shearman & Sterling.

Charles holds a J.D. from Pace University School of Law and a B.A. degree from Tufts University.

About Outcome Capital

Outcome Capital is a highly specialized life sciences and healthcare advisory and investment banking firm, providing innovative companies with a value-added, market-aligned approach to mergers & acquisitions, partnering and corporate finance. The firm leverages its proven ‘strategy-led execution’ approach to value enhancement by assisting management teams and their boards in navigating both financial and corporate markets and implementing the best path for success. The firm’s strength stems from its multi-disciplinary, industry experts who draw from their broad relationships and a wide range of scientific, operational, strategic and transactional expertise across the value chain. Comprised of former CEOs, business development executives, venture capitalists, PhD/MD-level scientists and clinicians, and experienced commercialization experts, Outcome’s team is driven to propel innovation from bench to bedside.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240807978894/en/